Can a biologic drug heal the skin barrier in kids with eczema?
NCT ID NCT04718870
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at how dupilumab, an injectable biologic drug, affects the skin barrier in 41 children aged 6 to 12 with moderate to severe atopic dermatitis (eczema). Researchers measured water loss through the skin after removing thin layers with tape to assess barrier function. The goal was to see if dupilumab improves the skin's ability to retain moisture.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dupilumab (a biologic drug given as an injection)
What this could lead to
If successful, this could show that dupilumab helps repair the skin barrier in children with eczema, potentially improving long-term skin health.
What could go wrong
This is a small, early-phase study with only 41 participants, so results may not apply to all children. It focuses on a skin measurement (water loss) rather than direct symptom relief.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number :8260001
Sheffield, S10 2TH, United Kingdom
-
Investigational Site Number :8400001
Denver, Colorado, 80206, United States
-
Investigational Site Number :8400002
Los Angeles, California, 90027, United States